Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
NCCN Hematology Congress
Progress in Molecular Markers that Predict Prognosis in AML
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
New York, NY—The era of personalized medicine is progressing. At the Fred Hutchinson Cancer Center, Seattle, WA, and at other centers, patients with intermediate-risk acute myeloid leukemia (AML) are now being tested for 3 molecular markers that predict prognosis.
Read Article
Advances in the Management of Chronic Lymphocytic Leukemia
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
New York, NY—Several advances have been made in the diagnosis and treatment of chronic lymphocytic leukemia (CLL), according to Susan O’Brien, MD, Chief, Acute Leukemia Section at M.D. Anderson Cancer Center, Houston.
Read Article
Treatment Delay Feasible in Asymptomatic Follicular Lymphoma
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
New York, NY—Evidence suggests that maintenance therapy, as well as initiation of therapy for newly diagnosed follicular lymphoma, can be delayed in asymptomatic patients with low tumor burden, according to Andrew Zelenetz, MD, Chief of Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Read Article
Novel Agents Improve Outcomes as Maintenance Therapy for Multiple Myeloma
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
Thalidomide (Thalomid), lenalidomide (Revlimid), and bortezomib (Velcade) have all shown benefit in the maintenance setting, said Steven Devine, MD, Professor of Medicine and Director of the Blood and Marrow Transplant Program, Ohio State University Comprehensive Cancer Center, Columbus, during the recent National Comprehensive Cancer Network (NCCN) 6th Congress on Hematologic Malignancies.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma